Navigation Links
Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Date:7/19/2012

to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements

This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products and product candidates and research and clinical programs now underway or planned, including without limitation SAR236553/REGN727, unforeseen safety issues resulting from the administration of products and product candidates in patients, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrativ
'/>"/>

SOURCE Sanofi and Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
2. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
5. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
6. Regeneron Announces March 2012 Investor Conference Presentations
7. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
8. Elsevier Launches International Journal for Parasitology: Parasites and Wildlife
9. Elsevier Launches a New Product Literature Database Solution for Life Science Professionals
10. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
11. infirst HEALTHCARE Established to Launch Novel Consumer Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
(Date:12/19/2014)... CITY, Calif. , Dec. 19, 2014 Bina ... , USA) announced today that they have been acquired ... 1,2 is a privately held company that provides ... of next generation sequencing (NGS) data for the academic ... the Roche Sequencing Unit, and will continue to focus ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... image of the carotid arteries that supply blood to the ... of Michigan Health System are using the system to diagnose ... Wire. Milwaukee GE Healthcare ... give physicians a non-invasive view of the heart and blood ...
... Finance Committee rejected Governor Jim Doyle's proposal for a 5 ... a plan to charge consumers for their music, book, art, ... turned down by the budget review panel. , ,After much ... entertainment called by some detractors the "iPod tax" ...
... your card in an ATM in San Francisco, the system ... But if you find yourself in an emergency room you'll ... series of tests because your medical record is a piece ... technology baffles users with ever-growing capabilities, including instant global transfer ...
Cached Biology Technology:GE Healthcare launches new medical scanner, places another in hospitals 2GE Healthcare launches new medical scanner, places another in hospitals 3Finance Committee rejects extra tax on Internet buys 2Finance Committee rejects extra tax on Internet buys 3Physician mindset slows adoption of electronic health records 2Physician mindset slows adoption of electronic health records 3Physician mindset slows adoption of electronic health records 4
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... cancer,has been announced by Agilent Technologies. The company ... advance of microarray-based,comparative genomic studies in cancer. According ... issue of the Proceedings of the,National Academy of ... Research Institute, Agilent has developed a specialised,microarray platform ...
... in life science and drug development : only "lucrative","markets" ... very promising drugs candidates or related research get canned,because ... if millions would have,been saved worldwide. The usual strategy ... that affect a "profitable" disease in addition to the,"non-profitable" ...
... "nano" - cancer detection using nanoparticles and MRI (magnetic ... one of the most important parts of the,work up ... the most appropriate treatment. And an essential part of ... been lymphatic spread. Current,methods include surgical removal of nodes ...
Cached Biology News:Breakthrough Microarray-based Technology for the Study of Cancer 2Finding Cures For Tropical Diseases: Is Open Source An Answer? 2Imaging Lymph Nodes with Nanoparticles 2
... 2D polyacrylamide gel electrophoresis (2D-PAGE) with biological ... core technology platform for proteomic analysis. 2D-PAGE ... samples limited only in the dynamic range ... proteins. Quantitative image based analysis of separated ...
... recombinant 177 amino acid polypeptide sequence corresponding ... MT1-MMP. Produced by activation of a ... E. coli periplasm. SPECIFIC ACTIVITY:The specific ... 140 mU/mg, where 1 U is the ...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Acetate Plate Sealers 100/Box...
Biology Products: